[HTML][HTML] Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
O Al-Sawaf, C Zhang, T Lu, MZ Liao… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2021•ncbi.nlm.nih.gov
PURPOSE The CLL14 study has established one-year fixed-duration treatment of
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic
lymphocytic leukemia. With all patients off treatment for at least three years, we report a
detailed analysis of minimal residual disease (MRD) kinetics and long-term outcome of
patients treated in the CLL14 study.
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic
lymphocytic leukemia. With all patients off treatment for at least three years, we report a
detailed analysis of minimal residual disease (MRD) kinetics and long-term outcome of
patients treated in the CLL14 study.
PURPOSE
The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all patients off treatment for at least three years, we report a detailed analysis of minimal residual disease (MRD) kinetics and long-term outcome of patients treated in the CLL14 study.
ncbi.nlm.nih.gov